MOB Share Price Performance
SEK 9.00
-22.66 (-71.57%)
18.2% undervalued intrinsic discount
SEK 11.00
Fair Value
Price SEK 9.00
AnalystConsensusTarget SEK 11.00
Fair ValueSEK 11.00
Share PriceSEK 9.00
18.2% undervalued intrinsic discount
MOB Community Narratives
AN
Fair Value SEK 11.00 18.2% undervalued intrinsic discount
Norway Expansion And EU Approvals Will Strengthen Future Position
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
MOB Community Fair Values
- SEK 11.00FV18.2% undervalued intrinsic discount117.61%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative1users have followed this narrative12 days ago author updated this narrative
Recent MOB News & Updates
No updates
Moberg Pharma AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 12, 2025
- Earnings per share (EPS)
- -5.35
- Gross Margin
- 65.23%
- Net Profit Margin
- -1,954.77%
- Debt/Equity Ratio
- 0%
Moberg Pharma AB (publ) Competitors
About MOB
- Founded
- 2006
- Employees
- 9
- CEO
- WebsiteView website
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Swedish Market Performance
- 7 Days: -2.2%
- 3 Months: 3.1%
- 1 Year: 3.0%
- Year to Date: -0.9%
Over the last 7 days, the market has dropped 2.9%, driven by losses in every sector, especially the Industrials sector. Overall the market has been flat in the last year. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading